Literature DB >> 22367950

Neutralization potential of the plasma of HIV-1 infected Indian patients in the context of anti-V3 antibody content and antiretroviral therapy. [corrected].

Alok Kumar Choudhary1, Raiees Andrabi, Somi Sankaran Prakash, Rajesh Kumar, Shubhasree Dutta Choudhury, Naveet Wig, Ashutosh Biswas, Anjali Hazarika, Kalpana Luthra.   

Abstract

We assessed the anti-V3 antibody content and viral neutralization potential of the plasma of 63 HIV-1-infected patients (antiretroviral naïve=39, treated=24) against four primary isolates (PIs) of clade C and a tier 1 clade B isolate SF162. Depletion and inhibition of anti-V3 antibodies in the plasma of five patients with high titers of anti-V3 antibodies led to modest change in the neutralization percentage against two PIs (range 0-21%). The plasma of antiretroviral-treated patients exhibited higher neutralization potential than that of the drug-naïve plasmas against the four PIs tested which was further evidenced by a follow-up study.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22367950     DOI: 10.1007/s12275-012-1246-y

Source DB:  PubMed          Journal:  J Microbiol        ISSN: 1225-8873            Impact factor:   3.422


  19 in total

1.  Structure of a V3-containing HIV-1 gp120 core.

Authors:  Chih-chin Huang; Min Tang; Mei-Yun Zhang; Shahzad Majeed; Elizabeth Montabana; Robyn L Stanfield; Dimiter S Dimitrov; Bette Korber; Joseph Sodroski; Ian A Wilson; Richard Wyatt; Peter D Kwong
Journal:  Science       Date:  2005-11-11       Impact factor: 47.728

2.  Extensive cross-reactive neutralizing antibody response in Indian patients with limited genetic diversity of HIV-1.

Authors:  Samir K Lakhashe; Smita S Kulkarni; Madhuri R Thakar; Manisha V Ghate; Ramesh S Paranjape
Journal:  Virology       Date:  2006-10-30       Impact factor: 3.616

3.  Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope.

Authors:  Susan Zolla-Pazner; Sandra Sharpe Cohen; Chavdar Krachmarov; Shixia Wang; Abraham Pinter; Shan Lu
Journal:  Virology       Date:  2007-12-03       Impact factor: 3.616

4.  Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity.

Authors:  Robyn L Stanfield; Miroslaw K Gorny; Susan Zolla-Pazner; Ian A Wilson
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.

Authors:  T R Fouts; J M Binley; A Trkola; J E Robinson; J P Moore
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

6.  Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection.

Authors:  J H Kim; J R Mascola; S Ratto-Kim; T C VanCott; L Loomis-Price; J H Cox; N L Michael; L Jagodzinski; C Hawkes; D Mayers; B L Gilliam; D C Birx; M L Robb
Journal:  AIDS Res Hum Retroviruses       Date:  2001-07-20       Impact factor: 2.205

7.  Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (Invirase) treatment.

Authors:  L Sarmati; E Nicastri; G el-Sawaf; L Ventura; A Salanitro; L Ercoli; S Vella; M Andreoni
Journal:  J Med Virol       Date:  1997-12       Impact factor: 2.327

8.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

9.  Isolation, propagation, and titration of human immunodeficiency virus type 1 from peripheral blood of infected individuals.

Authors:  Hanneke Schuitemaker; Neeltje A Kootstra
Journal:  Methods Mol Biol       Date:  2005

10.  Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy.

Authors:  Gülşen Ozkaya Sahin; Emma J Bowles; Joe Parker; Hannes Uchtenhagen; Enas Sheik-Khalil; Stephen Taylor; Oliver G Pybus; Barbro Mäkitalo; Lilian Walther-Jallow; Mats Spångberg; Rigmor Thorstensson; Adnane Achour; Eva Maria Fenyö; Guillaume B E Stewart-Jones; Anna-Lena Spetz
Journal:  PLoS Pathog       Date:  2010-09-02       Impact factor: 6.823

View more
  6 in total

1.  Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy.

Authors:  Raiees Andrabi; M A Makhdoomi; Rajesh Kumar; Manju Bala; Hilal Parray; Arjun Gupta; Ankita Kotnala; Velpandian Thirumurthy; Kalpana Luthra
Journal:  J Clin Immunol       Date:  2014-03-29       Impact factor: 8.317

2.  CD4-Binding Site Directed Cross-Neutralizing scFv Monoclonals from HIV-1 Subtype C Infected Indian Children.

Authors:  Sanjeev Kumar; Rajesh Kumar; Lubina Khan; Muzamil Ashraf Makhdoomi; Ramachandran Thiruvengadam; Madhav Mohata; Mudit Agarwal; Rakesh Lodha; Sushil Kumar Kabra; Subrata Sinha; Kalpana Luthra
Journal:  Front Immunol       Date:  2017-11-15       Impact factor: 7.561

3.  Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library.

Authors:  Lubina Khan; Rajesh Kumar; Ramachandran Thiruvengadam; Hilal Ahmad Parray; Muzamil Ashraf Makhdoomi; Sanjeev Kumar; Heena Aggarwal; Madhav Mohata; Abdul Wahid Hussain; Raksha Das; Raghavan Varadarajan; Jayanta Bhattacharya; Madhu Vajpayee; K G Murugavel; Suniti Solomon; Subrata Sinha; Kalpana Luthra
Journal:  Sci Rep       Date:  2017-03-23       Impact factor: 4.379

4.  Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India.

Authors:  Raiees Andrabi; Manju Bala; Rajesh Kumar; Naveet Wig; Anjali Hazarika; Kalpana Luthra
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

5.  A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy.

Authors:  Linlin Gu; Valentina Krendelchtchikova; Alexandre Krendelchtchikov; Robert A Oster; Kohtaro Fujihashi; Qiana L Matthews
Journal:  Virol J       Date:  2014-06-16       Impact factor: 4.099

6.  Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.

Authors:  Narayanaiah Cheedarla; K Lucia Precilla; Hemalatha Babu; K K Vidya Vijayan; Manickam Ashokkumar; Padmapriyadarsini Chandrasekaran; Nandagopal Kailasam; Jagadish Chandrabose Sundaramurthi; Soumya Swaminathan; Viswanath Buddolla; S Kalyanaraman Vaniambadi; V D Ramanathan; Luke Elizabeth Hanna
Journal:  Sci Rep       Date:  2017-04-24       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.